# 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

> **NCT02338960** · PHASE3 · COMPLETED · sponsor: **Palatin Technologies, Inc** · enrollment: 714 (actual)

## Conditions studied

- Hypoactive Sexual Desire Disorder

## Interventions

- **DRUG:** Bremelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02338960
- **Lead sponsor:** Palatin Technologies, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-08
- **Final completion:** 2017-06-29
- **Target enrollment:** 714 (ACTUAL)
- **Last updated:** 2021-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02338960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02338960, "2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02338960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*